<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314362</url>
  </required_header>
  <id_info>
    <org_study_id>SOVS2020-080</org_study_id>
    <nct_id>NCT04314362</nct_id>
  </id_info>
  <brief_title>Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)</brief_title>
  <official_title>A Single-center, Vehicle-controlled, Study to Evaluate Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azura Ophthalmics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azura Ophthalmics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, single-masked (the individual(s) performing efficacy and safety measures will
      be masked to treatment assignment for the patient(s) they are assessing), vehicle-controlled,
      randomized study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study with 6 visits. For all dose groups a screening visit will be followed by a
      baseline visit 14 days later (qualification period). At the end of the qualification period
      patients who still exhibit signs of Meibomian Gland Dysfunction (MGD) at the baseline visit
      will be enrolled into a 3-month treatment period. At the baseline (Day 0) visit, patients
      will be randomly assigned to receive either AZR-MD-001 ointment/semi-solid drug or AZR-MD-001
      vehicle twice-weekly.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 14, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy for MGD: change from baseline in meibomian gland secretion score (MGS)</measure>
    <time_frame>Day 14 to Month 3</time_frame>
    <description>The MGS can range from 0 (highly abnormal) to 45 (Normal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Observed rate of Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total OSDI: change from baseline in Total OSDI</measure>
    <time_frame>Day 14 to Month 3</time_frame>
    <description>Total OSDI can range in value from 0 (Normal) to 100 (Highly Abnormal)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>AZR-MD-001 Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 ointment/semi-solid drug (1.0%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 Active + Conventional Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 ointment/semi-solid drug (1.0%) plus Hylo-Forte®</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZR-MD-001 vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZR-MD-001 vehicle control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZR-MD-001 ointment/semi-solid drug</intervention_name>
    <description>AZR-MD-001 (1.0%) and suitable excipient</description>
    <arm_group_label>AZR-MD-001 Active</arm_group_label>
    <arm_group_label>AZR-MD-001 Active + Conventional Treatment</arm_group_label>
    <arm_group_label>AZR-MD-001 vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of meibomian gland obstruction (based on a meibomian gland secretion (MGS)
             score of ≤12 for 15 glands of the lower lid) in both eyes at the baseline visit

          -  Reported dry eye signs and symptoms within the past 3 months:

        Ocular Surface Disease Index (OSDI) score ≥ 13; TBUT &lt; 10 seconds in both eyes

        Exclusion Criteria:

          -  Uncontrolled ocular disease (except for MGD) or uncontrolled systemic disease

          -  Patient has glaucoma or ocular hypertension as demonstrated by an intraocular pressure
             (IOP) in either eye at screening of ≥24 mm Hg determined by Goldman applanation
             tonometry or has planned insertion/removal of glaucoma filtration shunts/devices
             during the study

          -  Corneal abnormality or disorder that impacts normal spreading of the tear film
             (keratoconus, pterygia, scarring) or corneal integrity

          -  Recent (within the past 3 months of the baseline visit) ocular surgery, trauma,
             herpes, or recurrent inflammation

          -  Contact lens use anticipated during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Charles Bosworth, PhD</last_name>
    <phone>715-559-8435</phone>
    <email>charles.bosworth@azuraophthalmics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Gleeson</last_name>
    <phone>+61 422 956 128</phone>
    <email>admin@azuraophthalmics.com</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

